Clinical Trials Logo

Oxytocin Deficiency clinical trials

View clinical trials related to Oxytocin Deficiency.

Filter by:
  • None
  • Page 1

NCT ID: NCT05319301 Completed - Social Isolation Clinical Trials

Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function. Hypopituitarism is associated with increased obesity, increased psychopathology, sexual and prosocial dysfunction despite appropriate hormone replacement. A few studies suggest the existence of a possible OT deficient state in hypopituitarism. In animal models, melatonin has shown to increase OT release. This study is designed to evaluate oxytocin values after administration of melatonin in adults (healthy volunteers and patients with hypopituitarism). The investigators hypothesize that OT response will be blunted following melatonin in patients with hypopituitarism compared to healthy controls.

NCT ID: NCT04902235 Completed - Social Isolation Clinical Trials

Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study)

Start date: July 6, 2021
Phase: Phase 4
Study type: Interventional

Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function. Hypopituitarism is associated with increased obesity, increased psychopathology, sexual and prosocial dysfunction despite appropriate hormone replacement. A few studies suggest the existence of a possible OT deficient state in hypopituitarism. In animal models, corticorelin hormone (CRH) has shown to increase OT release. This study is designed to evaluate oxytocin values after administration of CRH in adults (healthy volunteers and patients with hypopituitarism). The investigators hypothesize that OT response will be blunted following CRH in patients with hypopituitarism compared to healthy controls.

NCT ID: NCT04897802 Recruiting - Social Isolation Clinical Trials

Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)

Start date: September 13, 2021
Phase: Phase 4
Study type: Interventional

Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function. Hypopituitarism is associated with increased obesity, increased psychopathology, sexual and prosocial dysfunction despite appropriate hormone replacement. A few studies suggest the existence of a possible OT deficient state in hypopituitarism. In animal models, glucagon-like peptide 1 (GLP1) has shown to increase OT release. This study is designed to evaluate OT values after administration of GLP1 in adults (healthy volunteers and patients with hypopituitarism). The investigators hypothesize that OT response will be blunted following GLP1 receptor agonist (GLP1-RA) in patients with hypopituitarism compared to healthy controls.

NCT ID: NCT04427410 Completed - Clinical trials for Postpartum Depression

The Relationship Between Oxytocin Level and Postpartum Depression

Start date: July 20, 2019
Phase:
Study type: Observational

There are studies in the literature that associate oxytocin level with postpartum depression. This study was carried out to investigate the relationship between oxytocin levels measured during pregnancy and postpartum depression symptoms.